172 related articles for article (PubMed ID: 18489750)
1. Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage.
Kissela BM; Eckman MH
BMC Neurol; 2008 May; 8():17. PubMed ID: 18489750
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage.
Earnshaw SR; Joshi AV; Wilson MR; Rosand J
Stroke; 2006 Nov; 37(11):2751-8. PubMed ID: 17008607
[TBL] [Abstract][Full Text] [Related]
3. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
[TBL] [Abstract][Full Text] [Related]
4. Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign-Positive Acute Intracerebral Hemorrhage: The SPOTLIGHT and STOP-IT Randomized Clinical Trials.
Gladstone DJ; Aviv RI; Demchuk AM; Hill MD; Thorpe KE; Khoury JC; Sucharew HJ; Al-Ajlan F; Butcher K; Dowlatshahi D; Gubitz G; De Masi S; Hall J; Gregg D; Mamdani M; Shamy M; Swartz RH; Del Campo CM; Cucchiara B; Panagos P; Goldstein JN; Carrozzella J; Jauch EC; Broderick JP; Flaherty ML;
JAMA Neurol; 2019 Dec; 76(12):1493-1501. PubMed ID: 31424491
[TBL] [Abstract][Full Text] [Related]
5. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma.
Stein DM; Dutton RP; Kramer ME; Scalea TM
J Trauma; 2009 Jan; 66(1):63-72; discussion 73-5. PubMed ID: 19131807
[TBL] [Abstract][Full Text] [Related]
6. Recombinant activated factor VII for acute intracerebral hemorrhage.
Mayer SA; Brun NC; Begtrup K; Broderick J; Davis S; Diringer MN; Skolnick BE; Steiner T;
N Engl J Med; 2005 Feb; 352(8):777-85. PubMed ID: 15728810
[TBL] [Abstract][Full Text] [Related]
7. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.
Diringer MN; Skolnick BE; Mayer SA; Steiner T; Davis SM; Brun NC; Broderick JP
Stroke; 2008 Mar; 39(3):850-6. PubMed ID: 18239180
[TBL] [Abstract][Full Text] [Related]
8. Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage.
Al-Shahi Salman R
Cochrane Database Syst Rev; 2009 Oct; (4):CD005951. PubMed ID: 19821350
[TBL] [Abstract][Full Text] [Related]
9. Potential applicability of recombinant factor VIIa for intracerebral hemorrhage.
Flaherty ML; Woo D; Haverbusch M; Moomaw CJ; Sekar P; Sauerbeck L; Kissela B; Kleindorfer D; Broderick JP
Stroke; 2005 Dec; 36(12):2660-4. PubMed ID: 16269646
[TBL] [Abstract][Full Text] [Related]
10. Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.
Selin S; Tejani A
Issues Emerg Health Technol; 2006 Mar; (82):1-4. PubMed ID: 16602203
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia.
Yuan ZH; Jiang JK; Huang WD; Pan J; Zhu JY; Wang JZ
J Clin Neurosci; 2010 Jun; 17(6):685-93. PubMed ID: 20399668
[TBL] [Abstract][Full Text] [Related]
12. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
Mayer SA; Brun NC; Broderick J; Davis S; Diringer MN; Skolnick BE; Steiner T;
Stroke; 2005 Jan; 36(1):74-9. PubMed ID: 15569871
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.
Mayer SA; Brun NC; Begtrup K; Broderick J; Davis S; Diringer MN; Skolnick BE; Steiner T;
N Engl J Med; 2008 May; 358(20):2127-37. PubMed ID: 18480205
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever.
Naing C; Poovorawan Y; Mak JW; Aung K; Kamolratankul P
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):403-7. PubMed ID: 25692521
[TBL] [Abstract][Full Text] [Related]
15. Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?
Mayer SA; Davis SM; Skolnick BE; Brun NC; Begtrup K; Broderick JP; Diringer MN; Steiner T;
Stroke; 2009 Mar; 40(3):833-40. PubMed ID: 19150875
[TBL] [Abstract][Full Text] [Related]
16. Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage.
Diringer MN; Ferran JM; Broderick J; Davis S; Mayer SA; Steiner T; Brun NC; Skolnick BE; Christensen MC
Cerebrovasc Dis; 2007; 24(2-3):219-25. PubMed ID: 17630481
[TBL] [Abstract][Full Text] [Related]
17. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
18. Intracerebral hemorrhage: outcomes and eligibility for factor VIIa treatment in a National Stroke Registry.
Nadeau JO; Phillips S; Shi HS; Kapral MK; Gladstone DJ; Silver FL; Hill MD;
Cerebrovasc Dis; 2006; 22(4):271-5. PubMed ID: 16788301
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
20. Early recombinant factor VIIa therapy in acute intracerebral hemorrhage: promising approach.
Kumar S; Badrinath HR
Neurol India; 2006 Mar; 54(1):24-7. PubMed ID: 16679638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
